Michael Montgomery

Dr. Montgomery serves as Senior Advisor to Outcome Capital’s Biotechnology and Pharma practice. He brings extensive expertise in bench-top molecular biology research, clinical practice, drug development and marketing in both biotech and Big Pharma. He has developed several database solutions in the field of project management, resulting in two J&J IMAGE awards, and has spoken at multiple events on the successful application of software and data management solutions to real world medical problems. He has designed and run both US and Global Phase 2, 3 and 3b trials in cardiovascular disease, peripheral vascular disease, stroke, inflammatory diseases and the first Phase 4 Registry in Polycythemia Vera, REVEAL. He holds a key patent in the use of JAK1 inhibitors. Dr. Montgomery also led Incyte Corporation’s Global Medical Affairs department that he helped create. He has been CMO of both Caduceus Communications LLC, a clinical communications company and Lead Horse Technologies Inc., an AI company. He currently sits on the PhRMA Foundation Translational Medicine Grant Review Board and is a Co-Founder of Stable Solutions LLC, a medical and machine learning consultancy.

In addition to his experience in the biotech and pharma sectors, Dr. Montgomery’s medical and research career includes attending physician at Parkland and Dallas Veterans Hospitals, Cardiology Research Fellow at Washington University School of Medicine and Associate Professor at Temple Medical School Department of Anatomy & Cell Biology. Dr. Montgomery is widely published in peer-reviewed medical and scientific journals on various topics including stroke, peripheral and arterial vascular disease, dermatology and oncology. He received his MD from Columbia University College of Physicians and BSc degree from McGill University.